High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer

Clin Genitourin Cancer. 2019 Dec;17(6):476-479. doi: 10.1016/j.clgc.2019.07.022. Epub 2019 Aug 19.

Authors

Bryce Raymon Christensen¹, Pedro C Barata², Elisa M Ledet¹, Jodi L Layton², Brian E Lewis², Oliver Sartor³

Affiliations

¹ Tulane University School of Medicine, New Orleans, LA; Tulane Cancer Center, New Orleans, LA.
² Tulane Cancer Center, New Orleans, LA.
³ Tulane University School of Medicine, New Orleans, LA; Tulane Cancer Center, New Orleans, LA. Electronic address: osartor@tulane.edu.

PMID: 31537449
DOI: 10.1016/j.clgc.2019.07.022

No abstract available

Keywords: AR amplification; Androgen; PSA; Radiopharmaceutical; ctDNA.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Topical
Drug Administration Schedule
Humans
Male
Prostate-Specific Antigen / blood
Prostate-Specific Antigen / drug effects
Prostatic Neoplasms, Castration-Resistant / therapy*
Radium / administration & dosage*
Radium / pharmacology
Testosterone / administration & dosage*
Testosterone / pharmacology
Treatment Outcome

Substances

Testosterone
Radium-223
Prostate-Specific Antigen
Radium